Deciphera Pharmaceuticals Inc (DCPH) Gross Profit Margin starting from the first quarter 2024 to first quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Deciphera Pharmaceuticals Inc   (NASDAQ: DCPH)


Deciphera Pharmaceuticals Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DCPH Gross Profit Margin (Mar 31 2024)
Q1 		(Dec 31 2023)
Q4 		(Sep 30 2023)
Q3 		(Jun 30 2023)
Q2 		(Mar 31 2023)
Q1
Y / Y Revenue Change 34.55 %
Seq. Revenue Change -6.82 %
Revenue In Millions $45.00
Gross Profit Margin 95.36 %
Gross Profit Margin Total Ranking # 225
Gross Profit In Millions $42.91
Y / Y Gross Profit Change 30.2 %
Seq. Gross Profit Change -7.74 %


Commenting First Quarter 2024 Gross Profit Margin
Deciphera Pharmaceuticals Inc experienced contraction in Gross Profit by -7.74 % to $45 millions and Revenue by -6.82 %, while Gross Profit Margin fell to 95.36 %, above company*s average Gross Profit Margin.


Observing first quarter 2024 results within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 152 to 225.
Learn about Gross Margin
DCPH's Gross Profit Margin first quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 25
Overall # 223

Gross Profit Margin Statistics
High Average Low
99.89 % 74.01 % 16.62 %
(Jun 30 2020)   (Mar 31 2017)


DCPH Gross Income Trends • More of DCPH's Profitabilty Ratios • DCPH Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
DCPH's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
DCPH's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for DCPH's Competitors
Gross Profit Margin Profit Margin for Deciphera Pharmaceuticals Inc 's Suppliers
Gross Profit Margin Profit Margin for DCPH's Customers

You may also want to know
DCPH's Annual Growth Rates DCPH's Profitability Ratios DCPH's Asset Turnover Ratio DCPH's Dividend Growth
DCPH's Roe DCPH's Valuation Ratios DCPH's Financial Strength Ratios DCPH's Gross Profit Growth
DCPH's Roa DCPH's Inventory Turnover Ratio DCPH's Growth Rates DCPH's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2024 MRQ Gross ProfitMar 31 2024 MRQ Revenue
Bridgebio Pharma Inc   99.72 %$ 210.522  Millions$ 211.120  Millions
Corcept Therapeutics Inc  98.27 %$ 144.273  Millions$ 146.808  Millions
Ptc Therapeutics inc   98.24 %$ 206.418  Millions$ 210.118  Millions
Uniqure N v   98.23 %$ 8.335  Millions$ 8.485  Millions
Ionis Pharmaceuticals Inc   98.20 %$ 117.346  Millions$ 119.497  Millions
Therapeuticsmd Inc   97.86 %$ 0.229  Millions$ 0.234  Millions
Lexicon Pharmaceuticals Inc   97.26 %$ 1.099  Millions$ 1.130  Millions
Pyxis Oncology Inc   97.06 %$ 15.671  Millions$ 16.146  Millions
Macrogenics Inc   97.03 %$ 8.834  Millions$ 9.104  Millions
Blueprint Medicines Corporation  96.68 %$ 92.925  Millions$ 96.116  Millions
Gyre Therapeutics Inc   96.40 %$ 26.193  Millions$ 27.172  Millions
Travere Therapeutics Inc   96.36 %$ 39.870  Millions$ 41.374  Millions
Avadel Pharmaceuticals Plc  96.25 %$ 25.656  Millions$ 26.656  Millions
Adc Therapeutics Sa  95.86 %$ 17.305  Millions$ 18.053  Millions
Apellis Pharmaceuticals Inc   95.42 %$ 164.425  Millions$ 172.325  Millions
Deciphera Pharmaceuticals Inc   95.36 %$ 42.911  Millions$ 44.999  Millions
Zevra Therapeutics Inc   94.89 %$ 3.250  Millions$ 3.425  Millions
Urogen Pharma Ltd   94.46 %$ 17.053  Millions$ 18.053  Millions
Karyopharm Therapeutics Inc   94.23 %$ 31.215  Millions$ 33.126  Millions
Arcutis Biotherapeutics Inc   93.43 %$ 46.313  Millions$ 49.569  Millions
Amylyx Pharmaceuticals Inc   93.29 %$ 82.698  Millions$ 88.643  Millions
Rigel Pharmaceuticals Inc  93.14 %$ 27.509  Millions$ 29.534  Millions
Vanda Pharmaceuticals Inc   92.75 %$ 44.022  Millions$ 47.462  Millions
Regeneron Pharmaceuticals Inc   92.36 %$ 2,904.600  Millions$ 3,145.000  Millions
Agios Pharmaceuticals Inc   92.34 %$ 7.562  Millions$ 8.189  Millions
Silo Pharma Inc  91.90 %$ 0.017  Millions$ 0.018  Millions
Optinose Inc   91.73 %$ 13.649  Millions$ 14.880  Millions
Axsome Therapeutics Inc   91.60 %$ 68.702  Millions$ 74.999  Millions
Tg Therapeutics Inc   91.43 %$ 58.033  Millions$ 63.474  Millions
Ocular Therapeutix Inc   91.02 %$ 13.448  Millions$ 14.774  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.